Before the drug was available on the Chinese mai

Before the drug was available on the Chinese mai

nland, there was little effective therapy for the disease, and patients depended mainly on treat

ment such as respiratory and nutrition supports, said Xiong Hui, Beijing Medical Association rare disease c

ommittee member and Peking University First Hospital deputy director of pediatrics.

Spinraza debuted on the Chinese mainland having been fast-tracked through the marke

t approval process for rare disease drugs, which, available overseas since July, are urgently needed in China.

The drug began the approval process in September and was issued a license in February.

Premier Li Keqiang said in February that the government will step up efforts to gua

rantee more than 20 million rare disease patients have access to required medication.

www.ax142.cn

Avatar
weimiaow